New drug duo shows promise against tough lung cancer
NCT ID NCT05386888
First seen Nov 01, 2025 · Last updated May 18, 2026 · Updated 36 times
Summary
This study tested whether adding two drugs, GFH018 and toripalimab, to standard chemoradiation helps people with stage III non-small cell lung cancer that cannot be removed by surgery. The trial included 65 adults who had not been treated before. The main goal was to see how many patients' tumors shrank or disappeared. This is a disease control study because ongoing management is needed for this type of cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC STAGE III are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610000, China
Conditions
Explore the condition pages connected to this study.